SG11202108141VA - Novel cd40-binding antibodies - Google Patents

Novel cd40-binding antibodies

Info

Publication number
SG11202108141VA
SG11202108141VA SG11202108141VA SG11202108141VA SG11202108141VA SG 11202108141V A SG11202108141V A SG 11202108141VA SG 11202108141V A SG11202108141V A SG 11202108141VA SG 11202108141V A SG11202108141V A SG 11202108141VA SG 11202108141V A SG11202108141V A SG 11202108141VA
Authority
SG
Singapore
Prior art keywords
novel
binding antibodies
antibodies
binding
Prior art date
Application number
SG11202108141VA
Inventor
Der Vliet Johannes Jelle Van
Weerdt Iris De
Gruijl Tanja Denise De
Paul Parren
Aron Philip Kater
George Lodewijk Scheffer
Original Assignee
Lava Therapeutics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2022494A external-priority patent/NL2022494B1/en
Application filed by Lava Therapeutics B V filed Critical Lava Therapeutics B V
Publication of SG11202108141VA publication Critical patent/SG11202108141VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202108141VA 2019-02-01 2020-01-30 Novel cd40-binding antibodies SG11202108141VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2022494A NL2022494B1 (en) 2019-02-01 2019-02-01 Novel CD40-binding antibodies
NL2024087 2019-10-23
PCT/NL2020/050051 WO2020159368A1 (en) 2019-02-01 2020-01-30 Novel cd40-binding antibodies

Publications (1)

Publication Number Publication Date
SG11202108141VA true SG11202108141VA (en) 2021-08-30

Family

ID=71840475

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108141VA SG11202108141VA (en) 2019-02-01 2020-01-30 Novel cd40-binding antibodies

Country Status (11)

Country Link
US (1) US20220135694A1 (en)
EP (1) EP3917960A1 (en)
JP (1) JP2022519082A (en)
KR (1) KR20210141466A (en)
CN (1) CN113993893A (en)
AU (1) AU2020216250A1 (en)
BR (1) BR112021015238A8 (en)
CA (1) CA3128148A1 (en)
MX (1) MX2021009285A (en)
SG (1) SG11202108141VA (en)
WO (1) WO2020159368A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022034562A1 (en) * 2020-08-14 2022-02-17 GammaDelta Therapeutics Limited Multispecific anti-tcr delta variable 1 antibodies
CA3200826A1 (en) * 2020-12-10 2022-06-16 Paul Willem Henri Ida PARREN Antibodies that bind gamma-delta t cell receptors
AU2022224391A1 (en) * 2021-02-17 2023-08-24 Gammadelta Therapeutics Ltd Anti-tcr delta variable 1 antibodies
EP4355781A1 (en) 2021-06-18 2024-04-24 Autolus Limited Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseases
CN117616049A (en) * 2021-08-24 2024-02-27 江苏恒瑞医药股份有限公司 FAP/CD40 binding molecule and medical application thereof
WO2023067138A1 (en) 2021-10-21 2023-04-27 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
WO2023133394A1 (en) * 2022-01-05 2023-07-13 Inhibrx, Inc. Gamma delta t-cell-binding polypeptides and uses thereof
CA3208653A1 (en) * 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
EP4292609A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
CN116023495B (en) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 anti-CD40 nano antibody and preparation method and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211366A1 (en) * 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
JP5525729B2 (en) 2005-11-28 2014-06-18 ゲンマブ エー／エス Recombinant monovalent antibody and production method thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JP2012521768A (en) 2009-03-27 2012-09-20 ジモジェネティクス・インコーポレイテッド Compositions and methods for using multispecific binding proteins comprising antibody-receptor combinations
KR101224468B1 (en) 2009-05-20 2013-01-23 주식회사 파멥신 Bispecific antibody having a novel form and use thereof
CN103261220B (en) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 For generating the method for polyspecific and multivalent antibody
JP6393255B2 (en) 2012-04-20 2018-09-19 メルス ナムローゼ フェンノートシャップ Methods of producing heterodimeric IgG-like molecules, heterodimeric IgG-like molecules, heterodimeric antibodies, recombinant host cells, pharmaceutical compositions, methods of making host cells, and cultures
ES2744267T3 (en) 2012-11-21 2020-02-24 Pharmabcine Inc Double target antibody that targets VEGFR-2 and DLL4, and pharmaceutical composition comprising the same
EA202192165A1 (en) 2014-04-10 2021-12-31 Лава Терапьютикс Б.В. IMMUNOGLOBULINS BINDING HUMAN V9V2 T-CELL RECEPTORS

Also Published As

Publication number Publication date
KR20210141466A (en) 2021-11-23
JP2022519082A (en) 2022-03-18
WO2020159368A1 (en) 2020-08-06
MX2021009285A (en) 2021-11-12
EP3917960A1 (en) 2021-12-08
CA3128148A1 (en) 2020-08-06
BR112021015238A8 (en) 2022-08-16
AU2020216250A1 (en) 2021-08-26
BR112021015238A2 (en) 2022-02-15
CN113993893A (en) 2022-01-28
US20220135694A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
SG11202106214YA (en) Novel anti-ccr8 antibody
IL280780A (en) Anti-tigit antibodies
SG11202108141VA (en) Novel cd40-binding antibodies
IL279352A (en) Il-11ra antibodies
IL280013A (en) Anti-il36r antibodies
IL289112A (en) Anti-tigit antibodies
IL278010A (en) Galectin-10 antibodies
IL291068A (en) Anti-cd73 antibodies
IL284584A (en) Anti-tigit antibodies
IL277030A (en) Antibodies
SG11202106171WA (en) Anti-btla antibodies
IL281594A (en) Anti-klrg1 antibodies
ZA202108836B (en) Anti-epha4 antibody
GB201905150D0 (en) Ant-ige antibodies
GB2581174B (en) Antibodies against hEPCR
GB201806084D0 (en) Antibodies
GB201917480D0 (en) Antibodies
GB201900732D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
EP4081546A4 (en) Novel anti-fgfr2b antibodies
EP4081547A4 (en) Novel anti-fgfr2b antibodies
EP4081539A4 (en) Novel anti-fgfr2b antibodies
GB201911798D0 (en) Novel antibodies
GB201911799D0 (en) Novel Antibodies
GB201919280D0 (en) Antibodies